CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats

被引:33
作者
Wyde, PR
Moore-Poveda, DK
O'Hara, B
Ding, WD
Mitsner, B
Gilbert, BE
机构
[1] Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA
[2] Wyeth Ayerst Res Labs, Pearl River, NY 10965 USA
关键词
RSV; cotton rats; antiviral; pneumonia; prophylaxis; bronchiolitis;
D O I
10.1016/S0166-3542(98)00002-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CL387626 (4,4'-Bis[4,6-di[3-aminophenyl-N,N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazine-2-ylamino-biphenyl-2,2'-disulfonic acid, disodium salt), a compound synthesized by Wyeth-Ayerst Research Laboratories, was tested for its cytotoxicity and antiviral activity against respiratory syncytial virus (RSV) in tissue culture and in cotton rats. The median cell inhibitory (IC50) and median efficacious (EC50) concentrations of CL387626 against RSV in proliferating HEp2 or Vero tissue culture cells were determined to be 375 and 0.25 mu g/ml, respectively, giving the compound an apparent selective index (S.I.) of 1500. This compound also exhibited uncommon antiviral activity against RSV in cotton rats. In multiple experiments, a single 30 mg/kg dose of CL387626 administered intranasally 4 or 5 days prior to virus challenge, significantly inhibited pulmonary replication of RSV compared to that seen in control animals inoculated similarly with placebo (i.e. water). In contrast to these results, most lots of CL387626 failed to significantly inhibit pulmonary RSV replication when administered utilizing therapeutic administration schedules. Although some cytotoxicity was noted in tissue culture assays, no overt toxic effects were noted in any test animal, including those inoculated with >300 mg CL387626/kg, a dose approximately 150 times the apparent minimal efficacious dose (i.e. 1.9 mg/kg). (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:31 / 42
页数:12
相关论文
共 15 条
[1]  
BRADLEY JS, 1990, ANTIMICROB AGENTS CH, V34, P68
[2]  
CHANOCK RM, 1990, VIROLOGY, P963
[3]   Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults [J].
Dowell, SF ;
Anderson, LJ ;
Gary, HE ;
Erdman, DD ;
Plouffe, JF ;
File, TM ;
Marston, BJ ;
Breiman, RF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (03) :456-462
[4]  
GLEZEN WP, 1982, VIRAL INFECTIONS HUM, P337
[5]  
HALL CB, 1993, PEDIATRICS, V92, P501
[6]   Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus [J].
Johnson, S ;
Oliver, C ;
Prince, GA ;
Hemming, VG ;
Pfarr, DS ;
Wang, SC ;
Dormitzer, M ;
OGrady, J ;
Koenig, S ;
Tamura, JK ;
Woods, R ;
Bansal, G ;
Couchenour, D ;
Tsao, E ;
Hall, WC ;
Young, JF .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05) :1215-1224
[7]  
LAVIA WV, 1992, J PEDIATR-US, V121, P503
[8]   EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS-INFECTION IN WASHINGTON, DC .2. INFECTION AND DISEASE WITH RESPECT TO AGE, IMMUNOLOGICAL STATUS, RACE AND SEX [J].
PARROTT, RH ;
KIM, HW ;
ARROBIO, JO ;
HODES, DS ;
MURPHY, BR ;
BRANDT, CD ;
CAMARGO, E ;
CHANOCK, RM .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1973, 98 (04) :289-300
[9]   ENHANCED PULMONARY PATHOLOGY ASSOCIATED WITH THE USE OF FORMALIN-INACTIVATED RESPIRATORY SYNCYTIAL VIRUS-VACCINE IN COTTON RATS IS NOT A UNIQUE VIRAL PHENOMENON [J].
PIEDRA, PA ;
WYDE, PR ;
CASTLEMAN, WL ;
AMBROSE, MW ;
JEWELL, AM ;
SPEELMAN, DJ ;
HILDRETH, SW .
VACCINE, 1993, 11 (14) :1415-1423
[10]   Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid [J].
Prince, GA ;
Porter, DD .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03) :598-608